Analyst Ratings For NASDAQ:PSTI – Pluristem Therapeutics (NASDAQ:PSTI)

.

Some recent analyst ratings include

• 4/23/2018-MED Reiterated Rating of Positive.
• 10/6/2017-Seaport Global Securities Reiterated Rating of Buy.
• 1/10/2017-FBR & Co Reiterated Rating of Buy.

Recent Insider Trading Activity For NASDAQ:PSTI – Pluristem Therapeutics (NASDAQ:PSTI)
NASDAQ:PSTI – Pluristem Therapeutics (NASDAQ:PSTI) has insider ownership of 7.20% and institutional ownership of 4.17%.

• On 3/16/2018 Mark Germain, Director, sold 45,873 with an average share price of $1.48 per share and the total transaction amounting to $67,892.04.
• On 3/14/2018 Mark Germain, Director, sold 23,818 with an average share price of $1.50 per share and the total transaction amounting to $35,727.00.
• On 2/22/2016 Zami Aberman, CEO, bought 5,000 with an average share price of $1.33 per share and the total transaction amounting to $6,650.00.
• On 2/18/2016 Yaky Yanay, CFO, bought 5,000 with an average share price of $1.20 per share and the total transaction amounting to $6,000.00.
• On 2/16/2016 Yaky Yanay, CFO, bought 15,000 with an average share price of $0.95 per share and the total transaction amounting to $14,250.00.
• On 2/15/2016 Doron Shorrer, Director, bought 12,346 with an average share price of $0.81 per share and the total transaction amounting to $10,000.26.
• On 2/12/2016 Yaky Yanay, CFO, bought 5,000 with an average share price of $0.83 per share and the total transaction amounting to $4,150.00.

Recent Trading Activity for NASDAQ:PSTI – Pluristem Therapeutics (NASDAQ:PSTI)
Shares of NASDAQ:PSTI – Pluristem Therapeutics closed the previous trading session at 1.22 up +0.02 1.67% with shares trading hands.